EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Sickle Cell Disease: Historical Overview and Current Therapies

Oluwaseun O Babatunde, Madeleine G Bibby, Anthony Atala, Graça Almeida-Porada, Christopher D Porada iD

Prenatal Diagnosis · 10.06.2026

DOI: 10.1002/pd.70195 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Prenatal Diagnosis, online erschienen am 10.06.2026. Verfasst von Oluwaseun O Babatunde und 4 weiteren Autor:innen. Beteiligte Einrichtung: Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA. Die Arbeit nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sickle cell disease (SCD) affects millions worldwide, yet the limited treatment options currently available do not always adequately control the disease and carry significant side effects. At present, the only curative treatment is hematopoietic stem cell (HSC) transplantation, a procedure that carries considerable challenges and numerous risks to the patient, due in large part to the toxic conditioning regimens needed to obtain sufficient donor HSC engraftment. Thus, there is an urgent unmet medical need for novel SCD therapies that promise a cure for this devastating disease following a single treatment. Furthermore, while existing treatments often only commence in late childhood or adolescence, the clinical manifestations of SCD start during early infancy, placing the child at risk of permanent organ damage and potentially life‐threatening complications. In utero transplantation (IUTx) could correct SCD prior to disease onset, allowing the birth of a healthy baby who requires no treatment and is free from the immense burden this malady exerts. Herein, we provide a brief history of the discovery and characterization of SCD, an overview of current treatment options (highlighting their limitations and risks), and we introduce the concept that treating SCD prior to birth would avoid the hurdles of current treatment options.

Schlagwörter

Stichwörter der Autor:innen

HSC transplantationclinical managementhematopoietic stem cell (HSC)pathophysiologysickle cell disease

Autor:innen und Institutionen

  • Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA.

ORCID-Profile: Christopher D Porada

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Babatunde, O. O., Bibby, M. G., Atala, A., Almeida-Porada, G., & Porada, C. D. (2026). Sickle Cell Disease: Historical Overview and Current Therapies. Prenatal Diagnosis. https://doi.org/10.1002/pd.70195

Vancouver

Babatunde OO, Bibby MG, Atala A, Almeida-Porada G, Porada CD. Sickle Cell Disease: Historical Overview and Current Therapies. Prenatal Diagnosis. 2026. doi:10.1002/pd.70195

BibTeX
@article{Babatunde2026,
  author = {Babatunde, Oluwaseun O and Bibby, Madeleine G and Atala, Anthony and Almeida-Porada, Graça and Porada, Christopher D},
  title = {Sickle Cell Disease: Historical Overview and Current Therapies},
  journal = {Prenatal Diagnosis},
  year = {2026},
  doi = {10.1002/pd.70195}
}
Kostenlos starten →